JPWO2021183934A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2021183934A5 JPWO2021183934A5 JP2022554833A JP2022554833A JPWO2021183934A5 JP WO2021183934 A5 JPWO2021183934 A5 JP WO2021183934A5 JP 2022554833 A JP2022554833 A JP 2022554833A JP 2022554833 A JP2022554833 A JP 2022554833A JP WO2021183934 A5 JPWO2021183934 A5 JP WO2021183934A5
- Authority
- JP
- Japan
- Prior art keywords
- bcma
- subject
- cell maturation
- dihydrobromide
- maturation antigen
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025139609A JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202062989372P | 2020-03-13 | 2020-03-13 | |
| US62/989,372 | 2020-03-13 | ||
| PCT/US2021/022177 WO2021183934A1 (en) | 2020-03-13 | 2021-03-12 | A combination therapy with nirogacestat and a bcma-directed therapy and uses thereof |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Division JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2023517243A JP2023517243A (ja) | 2023-04-24 |
| JPWO2021183934A5 true JPWO2021183934A5 (https=) | 2024-03-21 |
| JP2023517243A5 JP2023517243A5 (https=) | 2024-03-21 |
| JP7781764B2 JP7781764B2 (ja) | 2025-12-08 |
Family
ID=75396879
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022554833A Active JP7781764B2 (ja) | 2020-03-13 | 2021-03-12 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025139609A Pending JP2025168430A (ja) | 2020-03-13 | 2025-08-25 | ニロガセスタットとｂｃｍａ指向療法での併用療法およびその使用 |
Country Status (17)
| Country | Link |
|---|---|
| US (1) | US20230121547A1 (https=) |
| EP (1) | EP4132515A1 (https=) |
| JP (2) | JP7781764B2 (https=) |
| KR (1) | KR20230009873A (https=) |
| CN (1) | CN115916188A (https=) |
| AR (1) | AR121566A1 (https=) |
| AU (1) | AU2021236340A1 (https=) |
| BR (1) | BR112022018251A2 (https=) |
| CA (1) | CA3171267A1 (https=) |
| CL (1) | CL2022002479A1 (https=) |
| CO (1) | CO2022014388A2 (https=) |
| IL (1) | IL296075A (https=) |
| MX (1) | MX2022011258A (https=) |
| PE (1) | PE20230614A1 (https=) |
| TW (1) | TW202200132A (https=) |
| WO (1) | WO2021183934A1 (https=) |
| ZA (1) | ZA202209989B (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3230245A1 (en) | 2021-09-01 | 2023-03-09 | Springworks Therapeutics, Inc. | Synthesis of nirogacestat |
| WO2023064872A1 (en) * | 2021-10-14 | 2023-04-20 | Precision Biosciences, Inc. | Combinations of anti-bcma car t cells and gamma secretase inhibitors |
| CN118338900A (zh) * | 2021-11-05 | 2024-07-12 | 斯普林渥克斯治疗有限公司 | 含尼罗加司他的组合物和治疗 |
| CN118302412A (zh) * | 2021-11-23 | 2024-07-05 | 梯瓦制药国际有限责任公司 | Nirogacestat盐的固态形式 |
| US12138246B2 (en) | 2022-05-20 | 2024-11-12 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| US11951096B2 (en) | 2022-05-20 | 2024-04-09 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| IL316750A (en) | 2022-05-20 | 2025-01-01 | Springworks Therapeutics Inc | Treatments with Nirogesstat |
| US12036207B2 (en) | 2022-05-20 | 2024-07-16 | Springworks Therapeutics, Inc. | Treatments with nirogacestat |
| EP4678635A1 (en) * | 2023-03-09 | 2026-01-14 | Crystal Pharmaceutical (Suzhou) Co., Ltd. | Crystal form of nirogacestat dihydrobromate, and preparation method therefor and use thereof |
Family Cites Families (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10149855B2 (en) * | 2014-02-05 | 2018-12-11 | The Trustees Of Columbia University In The City Of New York | Gamma-secretase inhibition reduce APOC3 levels and plasma triglycerides |
| AU2016297793A1 (en) * | 2015-07-24 | 2018-02-08 | Oncotracker, Inc. | Gamma secretase modulators for the treatment of immune system dysfunction |
| IL268349B2 (en) * | 2017-02-17 | 2024-08-01 | Hutchinson Fred Cancer Res | Combination therapies for treatment of bcma-related cancers and autoimmune disorders |
| WO2018201056A1 (en) * | 2017-04-28 | 2018-11-01 | Novartis Ag | Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor |
| EP3615068A1 (en) * | 2017-04-28 | 2020-03-04 | Novartis AG | Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor |
| CN110622566B (zh) | 2017-05-05 | 2021-04-20 | 华为技术有限公司 | 一种辅助数据传输方法、设备及系统 |
| SG11202003427XA (en) * | 2017-11-06 | 2020-05-28 | Juno Therapeutics Inc | Combination of a cell therapy and a gamma secretase inhibitor |
| WO2019094626A1 (en) * | 2017-11-08 | 2019-05-16 | Fred Hutchinson Cancer Research Center | Bispecific antibody compositions and related methods for improved pretargeted radioimunotherapies |
| US20210069194A1 (en) * | 2018-01-17 | 2021-03-11 | Mingsight Pharmaceuticals, Inc. | Combination therapy for the treatment of cancer |
| SG11202011589WA (en) * | 2018-05-24 | 2020-12-30 | Ayala Pharmaceuticals Inc | Compositions comprising bisfluoroalkyl-1,4-benzodiazepinone compounds and immunotherapeutics and methods of use thereof |
| UY38251A (es) * | 2018-06-01 | 2019-12-31 | Novartis Ag | Moléculas de unión contra bcma y usos de las mismas |
| BR112021020409A2 (pt) * | 2019-04-10 | 2021-12-07 | Glaxosmithkline Ip Dev Ltd | Terapia de combinação com anticorpo anti-bcma e inibidor de gama-secretase |
| EP4010322B1 (en) | 2019-08-09 | 2025-11-05 | Pfizer Inc. | Solid state forms of (s)-2-(((s)-6,8-difluoro-1,2,3,4-tetrahydronaphthalen-2-yl)amino)-n-(1-(2-methyl-1-(neopentylamino)propan-2-yl)-1h-imidazol-4-yl)pentanamide and uses thereof |
-
2021
- 2021-03-12 WO PCT/US2021/022177 patent/WO2021183934A1/en not_active Ceased
- 2021-03-12 TW TW110108930A patent/TW202200132A/zh unknown
- 2021-03-12 CA CA3171267A patent/CA3171267A1/en active Pending
- 2021-03-12 EP EP21716907.7A patent/EP4132515A1/en active Pending
- 2021-03-12 BR BR112022018251A patent/BR112022018251A2/pt unknown
- 2021-03-12 PE PE2022001961A patent/PE20230614A1/es unknown
- 2021-03-12 KR KR1020227034017A patent/KR20230009873A/ko active Pending
- 2021-03-12 CN CN202180034598.4A patent/CN115916188A/zh active Pending
- 2021-03-12 JP JP2022554833A patent/JP7781764B2/ja active Active
- 2021-03-12 AU AU2021236340A patent/AU2021236340A1/en active Pending
- 2021-03-12 IL IL296075A patent/IL296075A/en unknown
- 2021-03-12 MX MX2022011258A patent/MX2022011258A/es unknown
- 2021-03-12 US US17/906,089 patent/US20230121547A1/en active Pending
- 2021-03-12 AR ARP210100641A patent/AR121566A1/es unknown
-
2022
- 2022-09-07 ZA ZA2022/09989A patent/ZA202209989B/en unknown
- 2022-09-12 CL CL2022002479A patent/CL2022002479A1/es unknown
- 2022-10-10 CO CONC2022/0014388A patent/CO2022014388A2/es unknown
-
2025
- 2025-08-25 JP JP2025139609A patent/JP2025168430A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US20220088196A1 (en) | Means and Methods for Treating Tumorous Diseases | |
| DK2055313T3 (en) | Treatment of Hematologic Malignancies Related to Circulating Tumor Cells Using Chimeric Anti-CD20 Antibody | |
| Wu et al. | CTLA-4 blockade expands infiltrating T cells and inhibits cancer cell repopulation during the intervals of chemotherapy in murine mesothelioma | |
| Sacchi et al. | Treatment of B-cell non-Hodgkin's lymphoma with anti CD 20 monoclonal antibody Rituximab | |
| EP3800203A1 (en) | Multispecific binding proteins targeting caix, ano1, mesothelin,trop2, cea, or claudin-18.2 | |
| KR20230008197A (ko) | 암을 치료하기 위한 방법, 요법 및 용도 | |
| EA004107B1 (ru) | Комбинированная терапия в-клеточных лимфом, предусматривающая введение антитела против cd20 | |
| JP2007512243A5 (https=) | ||
| KR20230069181A (ko) | 암 치료를 위한 방법, 요법 및 용도 | |
| Robak et al. | Antibody therapy alone and in combination with targeted drugs in chronic lymphocytic leukemia | |
| JPWO2021183934A5 (https=) | ||
| KR20200010472A (ko) | 항-cd19 항체 및 베네토클락스 조합 치료에 대한 치료 패러다임 | |
| CA3087346A1 (en) | Combination immunotherapy and chemotherapy for the treatment of a hematological malignancy | |
| Jäeger et al. | Rituximab (anti‐CD20 monoclonal antibody) as consolidation of first‐line CHOP chemotherapy in patients with follicular lymphoma: a phase II study | |
| Wang et al. | Bispecific antibodies for multiple myeloma: recent advancements and strategies for increasing their efficacy | |
| Banerjee et al. | Emerging new cell therapies/immune therapies in B-cell non-Hodgkin's lymphoma | |
| CN101331151A (zh) | 治疗肿瘤性疾病的方式和方法 | |
| Longo | Biologic agents and approaches in the management of patients with lymphoma: a critical appraisal | |
| JPWO2020222668A5 (https=) | ||
| Rai et al. | Monoclonal antibodies in chronic lymphocytic leukemia | |
| Ayyappan et al. | SOHO State of the Art Updates and Next Questions| Manuscript Title: Bispecific T-Cell Engagers: Sequencing, B-Cell Maturation Antigen, GPRC5D, and Resistance | |
| WO2026053158A1 (en) | Dazostinag or conjugates thereof for treatment of neuroendocrine neoplasms | |
| Zent | Monoclonal antibody therapy in chronic lymphocytic leukemia | |
| AU2013202375B2 (en) | Means and Methods for the Treatment of Tumorous Diseases | |
| Batlevi et al. | Chimeric Antigen Receptor T Cells for Lymphomas: Methods, Data, and Challenges |